Companies TherapeuticsMD, Inc.
TherapeuticsMD (TXMD): executive pay, fiscal 2024
Free brief. Every figure links to the company’s own filing.
Email me TherapeuticsMD, Inc.’s executive pay brief as a PDF
It arrives in about 2 minutes, with every figure cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $1,019,817FY2023
- $759,174FY2024
CEO total pay was $759,174 in fiscal 2024, down from $1,019,817 in fiscal 2023.
FY2024: salary $500,000 · bonus $0 · stock awards $0 · option awards $0
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Marlan Walker | $500,000 | $0 | $0 | $0 | $250,000 | $0 | $9,174 | $759,174 |
| Chief Executive Officer | ||||||||
| Joseph Ziegler | 120,000 | 0 | — | 0 | 0 | 0 | 0 | 120,000 |
| Principal Financial and Accounting Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2024 total | FY2023 total | FY2022 total | Δ FY2023→2024 |
|---|---|---|---|---|
| Marlan Walker | $759,174 | $1,019,817 | — | ↓ −260,643 |
| Joseph Ziegler | 120,000 | 82,900 | — | ↑ +37,100 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The Compensation Committee makes every effort to ensure the executive compensation program is consistent with the company's values and is aligned with its business strategy and corporate goals.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | — |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2024
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Marlan Walker | RSU | — | — | — | 70,000 | — | $358,400 |
| Joseph Ziegler | RSU | — | — | — | 7,500 | — | 30,000 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Marlan Walker | $358,400 | $0 | $0 | 0.0% |
| Joseph Ziegler | 30,000 | 0 | 0 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2024
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Marlan Walker | RSU | 1,733 | — | $1,490 |
| Marlan Walker | RSU | 5,200 | — | 4,472 |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Tommy G. ThompsonIndependent · Board Chair · Audit | $101,758 | $0 | $0 | — | $0 | $101,758 |
| Cooper C. CollinsIndependent · Audit (Chair) · Compensation | 99,500 | 0 | 0 | — | 0 | 99,500 |
| Gail K. Naughton, Ph.DIndependent · Compensation (Chair) | 77,500 | 0 | 0 | — | 0 | 77,500 |
| Justin RobertsIndependent · Audit · Compensation | 0 | 0 | 0 | — | 0 | — |
Board fee structure and ownership guideline
| Annual cash retainer | $57,500 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 20,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2024 |
|---|---|
| Cash retainers and fees | $278,758 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $278,758 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names TherapeuticsMD as a peer
Companies that benchmark against TXMD
1 company names TXMD as a compensation peer
The list of companies that name TXMD as a peer is temporarily unavailable — recheck shortly.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | TherapeuticsMD, Inc. | 2024 | Marlan Walker | $500,000 | $0 | $0 | $250,000 | $759,174 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
No say-on-pay vote is on file for this company.
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (12 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Marlan Walker. DEF 14A, filed 2025-11-03. Section “Fiscal Year 2024 Summary Compensation Table” · page 17. As printed: 759,174. View filing ↗
- Section 01, Joseph Ziegler. DEF 14A, filed 2025-11-03. Section “Fiscal Year 2024 Summary Compensation Table” · page 17. As printed: 120,000. View filing ↗
- Section 03, Marlan Walker RSU. DEF 14A, filed 2025-11-03. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Joseph Ziegler RSU. DEF 14A, filed 2025-11-03. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 08, Tommy G. Thompson. DEF 14A, filed 2025-11-03. Section “Director Compensation”. As printed: 101,758. View filing ↗
- Section 08, Cooper C. Collins. DEF 14A, filed 2025-11-03. Section “Director Compensation”. As printed: 99,500. View filing ↗
- Section 08, Gail K. Naughton, Ph.D. DEF 14A, filed 2025-11-03. Section “Director Compensation”. As printed: 77,500. View filing ↗
- Section 08, Justin Roberts. DEF 14A, filed 2025-11-03. Section “Director Compensation”. As printed: —. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 278,758 + equity 0 + all other 0 = 278,758, summed across the director compensation table rows.
- TherapeuticsMD, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2025-11-03. CEO total compensation as printed in TherapeuticsMD, Inc.'s own proxy. As printed: 759,174. View filing ↗
Track every company like this one
Velarion Pro: every company and person, custom peer sets, exports and alerts. $1,200/year.